Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.